Altimmune, Inc. announced Impairment loss on intangible asset of $12.4 million was recognized during the three months ended December 31, 2023 related to the acquired In-Process Research and Development asset associated with HepTcell. The overall response in the Phase 2 trial was deemed to be insufficient to warrant further advancement. As a result, any further development related to HepTcell has been stopped.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.395 USD | -11.91% | -14.39% | -43.16% |
Apr. 29 | Altimmune Shares Decline After Guggenheim Downgrade | MT |
Apr. 29 | Guggenheim Downgrades Altimmune to Neutral From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.16% | 515M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023